# Balancing Speed and Cost: Economic Insights from Rapid Diagnostic Testing in Bloodstream Infections

**Authors:** Gergana Lengerova, Ralitsa Raycheva, Michael M. Petrov, Todor Kantardjiev

PMC · DOI: 10.3390/antibiotics15030320 · Antibiotics · 2026-03-20

## TL;DR

This study examines how rapid diagnostic tests for bloodstream infections affect patient outcomes and hospital costs, finding mixed economic benefits.

## Contribution

The study provides real-world evidence on the clinical and economic impacts of rapid diagnostic methods for bloodstream infections.

## Key findings

- Rapid diagnostics did not significantly affect mortality or length of stay.
- mPCR increased antibiotic use and related costs compared to standard methods.
- FISH and mPCR showed lower but not statistically significant hospital costs.

## Abstract

Background: Rapid diagnostic tests (RDTs) for bloodstream infections (BSIs) reduce time to pathogen identification, yet evidence on their real-world economic and clinical value remains inconsistent. This study aimed to compare clinical outcomes, antibiotic utilization, and hospital costs associated with different rapid microbiological identification methods versus standard culture. Methods: A retrospective observational study was conducted in a tertiary university hospital including 115 hospitalized patients with suspected or confirmed BSIs. Multiplex PCR (mPCR), fluorescence in situ hybridization (FISH), and MALDI-TOF MS were compared with conventional culture. Outcomes included mortality, length of stay, antibiotic-days, and direct and indirect hospital costs. Nonparametric and exploratory adjusted analyses were performed. Results: No significant differences were observed across diagnostic groups for age, sex, mortality, or length of stay. Patients tested with mPCR showed higher empirical and total antibiotic-days and increased antibiotic-related costs (p < 0.05). Median direct and indirect hospital costs were numerically lower with FISH and mPCR but did not reach statistical significance. Adjusted analyses confirmed that diagnostic modality was not independently associated with mortality or costs. Conclusions: Rapid diagnostics accelerate identification but demonstrate heterogeneous downstream clinical and economic effects. Their value appears to depend more on local implementation and antimicrobial stewardship integration than on diagnostic speed alone.

## Full-text entities

- **Genes:** ASPM (assembly factor for spindle microtubules) [NCBI Gene 259266] {aka ASP, Calmbp1, MCPH5}
- **Diseases:** BSIs (MESH:D018805), tachypnea (MESH:D059246), fever (MESH:D005334), death (MESH:D003643), bacteremia (MESH:D016470), injury to (MESH:D014947), leukocytosis (MESH:D007964), fungemia (MESH:D016469), systemic infection (MESH:D012141), infection (MESH:D007239), tachycardia (MESH:D013610), leukopenia (MESH:D007970), critically (MESH:D016638)
- **Chemicals:** LOS (-)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023472/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023472/full.md

---
Source: https://tomesphere.com/paper/PMC13023472